HPV vaccination improves immune response in children with respiratory papillomatosis

Abstract Recurrent respiratory papillomatosis (RRP) is a pathology characterized by the presence of neoplasm in the epithelium of the airways, where the larynx is the main affected organ. The cause of this disease is the low-risk Human Papillomavirus (HPV), where subtypes 6 and 11 are the most frequ...

Full description

Saved in:
Bibliographic Details
Main Authors: Miguel A. Prieto-Islas, Esmeralda Godoy-Dahbura, Diana C. Villalpando-Sánchez, Cristina Cortés-Benavides, Eduardo Hernández-Cuellar, Denisse Castro-Eguiluz, Hiram Alvarez-Neri, Oscar Medina-Contreras
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-025-14787-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849333074860441600
author Miguel A. Prieto-Islas
Esmeralda Godoy-Dahbura
Diana C. Villalpando-Sánchez
Cristina Cortés-Benavides
Eduardo Hernández-Cuellar
Denisse Castro-Eguiluz
Hiram Alvarez-Neri
Oscar Medina-Contreras
author_facet Miguel A. Prieto-Islas
Esmeralda Godoy-Dahbura
Diana C. Villalpando-Sánchez
Cristina Cortés-Benavides
Eduardo Hernández-Cuellar
Denisse Castro-Eguiluz
Hiram Alvarez-Neri
Oscar Medina-Contreras
author_sort Miguel A. Prieto-Islas
collection DOAJ
description Abstract Recurrent respiratory papillomatosis (RRP) is a pathology characterized by the presence of neoplasm in the epithelium of the airways, where the larynx is the main affected organ. The cause of this disease is the low-risk Human Papillomavirus (HPV), where subtypes 6 and 11 are the most frequent. The only proven effective treatment is surgical resection of the lesions, and although there are adjunctive treatments to try to reduce the recurrence of neoplasms, it has not been proven that there is an effective alternative that achieves this effect. A proposal as adjuvant therapy is the HPV vaccine; although used in adults to treat the disease, the effect it has on immunological changes in a pediatric population with PRR has not been studied, so the objective of this work is to assess the efficacy of vaccination as an adjuvant treatment, by observing the immunological changes that are generated after vaccination, measuring the antibody titer as well as the cytokine profile present in the patients and relating it to the impact at the clinical in pediatric population. For this, blood samples and biopsies obtained by laryngeal surgery from 10 patients before and 6 months after completing the HPV vaccination scheme were compared. Viral load of the HPV6/11 serotypes was measured by qPCR, observing a decrease in copy number of both subtypes after vaccination. The antibody titer in the serum of the same patients was measured by ELISA, observing an increase in the amount of IgG antibodies without finding modifications in the IgM antibodies against HPV L1 protein. In addition, HPV vaccination was associated with a decrease in the immunosuppressive cytokine IL-10 in papilloma tissue and a significant increase in the pro-inflammatory cytokine TNFα in serum, suggesting a shift towards a Th1-mediated immune response. All these changes had an impact on the number of surgeries that were performed to remove the neoplasms, where there was a decrease in these during a six-month follow-up after vaccination. In conclusion, the vaccination as adjuvant therapy increased the number of IgG antibodies against the virus. It increased the amount of pro-inflammatory cytokines at the systemic level, reducing the viral load and the number of recurrences of papillomas.
format Article
id doaj-art-7d26d44e1a9a46c7af0329dd72ef7fd2
institution Kabale University
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-7d26d44e1a9a46c7af0329dd72ef7fd22025-08-20T03:46:00ZengNature PortfolioScientific Reports2045-23222025-08-0115111010.1038/s41598-025-14787-2HPV vaccination improves immune response in children with respiratory papillomatosisMiguel A. Prieto-Islas0Esmeralda Godoy-Dahbura1Diana C. Villalpando-Sánchez2Cristina Cortés-Benavides3Eduardo Hernández-Cuellar4Denisse Castro-Eguiluz5Hiram Alvarez-Neri6Oscar Medina-Contreras7Immunometabolism Laboratory; Epidemiology, Endocrinology & Nutrition Research Unit, Mexico Children’s HospitalDepartment of Ophthalmology, Mexico Children’s HospitalImmunometabolism Laboratory; Epidemiology, Endocrinology & Nutrition Research Unit, Mexico Children’s HospitalDepartment of Ophthalmology, Mexico Children’s HospitalDepartment of Morphology, Center for Basic Sciences, Autonomous University of AguascalientesDepartment of Clinical Research, National Cancer InstituteDepartment of Ophthalmology, Mexico Children’s HospitalImmunometabolism Laboratory; Epidemiology, Endocrinology & Nutrition Research Unit, Mexico Children’s HospitalAbstract Recurrent respiratory papillomatosis (RRP) is a pathology characterized by the presence of neoplasm in the epithelium of the airways, where the larynx is the main affected organ. The cause of this disease is the low-risk Human Papillomavirus (HPV), where subtypes 6 and 11 are the most frequent. The only proven effective treatment is surgical resection of the lesions, and although there are adjunctive treatments to try to reduce the recurrence of neoplasms, it has not been proven that there is an effective alternative that achieves this effect. A proposal as adjuvant therapy is the HPV vaccine; although used in adults to treat the disease, the effect it has on immunological changes in a pediatric population with PRR has not been studied, so the objective of this work is to assess the efficacy of vaccination as an adjuvant treatment, by observing the immunological changes that are generated after vaccination, measuring the antibody titer as well as the cytokine profile present in the patients and relating it to the impact at the clinical in pediatric population. For this, blood samples and biopsies obtained by laryngeal surgery from 10 patients before and 6 months after completing the HPV vaccination scheme were compared. Viral load of the HPV6/11 serotypes was measured by qPCR, observing a decrease in copy number of both subtypes after vaccination. The antibody titer in the serum of the same patients was measured by ELISA, observing an increase in the amount of IgG antibodies without finding modifications in the IgM antibodies against HPV L1 protein. In addition, HPV vaccination was associated with a decrease in the immunosuppressive cytokine IL-10 in papilloma tissue and a significant increase in the pro-inflammatory cytokine TNFα in serum, suggesting a shift towards a Th1-mediated immune response. All these changes had an impact on the number of surgeries that were performed to remove the neoplasms, where there was a decrease in these during a six-month follow-up after vaccination. In conclusion, the vaccination as adjuvant therapy increased the number of IgG antibodies against the virus. It increased the amount of pro-inflammatory cytokines at the systemic level, reducing the viral load and the number of recurrences of papillomas.https://doi.org/10.1038/s41598-025-14787-2
spellingShingle Miguel A. Prieto-Islas
Esmeralda Godoy-Dahbura
Diana C. Villalpando-Sánchez
Cristina Cortés-Benavides
Eduardo Hernández-Cuellar
Denisse Castro-Eguiluz
Hiram Alvarez-Neri
Oscar Medina-Contreras
HPV vaccination improves immune response in children with respiratory papillomatosis
Scientific Reports
title HPV vaccination improves immune response in children with respiratory papillomatosis
title_full HPV vaccination improves immune response in children with respiratory papillomatosis
title_fullStr HPV vaccination improves immune response in children with respiratory papillomatosis
title_full_unstemmed HPV vaccination improves immune response in children with respiratory papillomatosis
title_short HPV vaccination improves immune response in children with respiratory papillomatosis
title_sort hpv vaccination improves immune response in children with respiratory papillomatosis
url https://doi.org/10.1038/s41598-025-14787-2
work_keys_str_mv AT miguelaprietoislas hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT esmeraldagodoydahbura hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT dianacvillalpandosanchez hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT cristinacortesbenavides hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT eduardohernandezcuellar hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT denissecastroeguiluz hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT hiramalvarezneri hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis
AT oscarmedinacontreras hpvvaccinationimprovesimmuneresponseinchildrenwithrespiratorypapillomatosis